Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Cochat

Showing results (181-190 of 225) with videos related to

Pageof 23
Sort By:
Kidney International|December 18, 2009
Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcomeJérôme Harambat, Sonia Fargue, Cécile Acquaviva, et al.
Kidney International|July 3, 2009
Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1Sonia Fargue, Jérôme Harambat, Marie-France Gagnadoux, et al.
Nature Immunology|June 2, 2009
Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosusAgnès Doreau, Alexandre Belot, Jérémy Bastid, et al.
Journal of the American Society of Nephrology : JASN|October 22, 2003
A cluster of mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with abnormal expression of uromodulinKarin Dahan, Olivier Devuyst, Michèle Smaers, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 17, 2012
Familial hypomagnesemia with hypercalciuria and nephrocalcinosis: phenotype-genotype correlation and outcome in 32 patients with CLDN16 or CLDN19 mutationsAstrid Godron, Jérôme Harambat, Valérie Boccio, et al.
Nefrologia : Publicacion Oficial De La Sociedad Espanola Nefrologia|May 7, 2014
European renal best practice guideline on the management and evaluation of the kidney donor and recipientJulio Pascual, Daniel Abramowicz, Pierre Cochat, et al.
Pediatric Nephrology (Berlin, Germany)|September 9, 2020
Adherence to cysteamine in nephropathic cystinosis: A unique electronic monitoring experience for a better understanding. A prospective cohort study: CrYSTobsSegolene Gaillard, Laurent Roche, Sandrine Lemoine, et al.
Kidney International Reports|July 11, 2022
Improved Outcome of Infantile Oxalosis Over Time in Europe: Data From the OxalEurope RegistryLisa J Deesker, Sander F Garrelfs, Giorgia Mandrile, et al.
BMJ Evidence-Based Medicine|February 14, 2023
Rapid access to innovative medicinal products while ensuring relevant health technology assessment. Position of the French National Authority for HealthAntoine Vanier, Judith Fernandez, Sophie Kelley, et al.
BMC Nephrology|July 5, 2017
Worldwide view of nephropathic cystinosis: results from a survey from 30 countriesAurélia Bertholet-Thomas, Julien Berthiller, Velibor Tasic, et al.
Pageof 23

Showing results (181-190 of 225) with videos related to

Sort By:
Pageof 23
Kidney International|December 18, 2009
Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcomeJérôme Harambat, Sonia Fargue, Cécile Acquaviva, et al.
Kidney International|July 3, 2009
Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1Sonia Fargue, Jérôme Harambat, Marie-France Gagnadoux, et al.
Nature Immunology|June 2, 2009
Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosusAgnès Doreau, Alexandre Belot, Jérémy Bastid, et al.
Journal of the American Society of Nephrology : JASN|October 22, 2003
A cluster of mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with abnormal expression of uromodulinKarin Dahan, Olivier Devuyst, Michèle Smaers, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 17, 2012
Familial hypomagnesemia with hypercalciuria and nephrocalcinosis: phenotype-genotype correlation and outcome in 32 patients with CLDN16 or CLDN19 mutationsAstrid Godron, Jérôme Harambat, Valérie Boccio, et al.
Nefrologia : Publicacion Oficial De La Sociedad Espanola Nefrologia|May 7, 2014
European renal best practice guideline on the management and evaluation of the kidney donor and recipientJulio Pascual, Daniel Abramowicz, Pierre Cochat, et al.
Pediatric Nephrology (Berlin, Germany)|September 9, 2020
Adherence to cysteamine in nephropathic cystinosis: A unique electronic monitoring experience for a better understanding. A prospective cohort study: CrYSTobsSegolene Gaillard, Laurent Roche, Sandrine Lemoine, et al.
Kidney International Reports|July 11, 2022
Improved Outcome of Infantile Oxalosis Over Time in Europe: Data From the OxalEurope RegistryLisa J Deesker, Sander F Garrelfs, Giorgia Mandrile, et al.
BMJ Evidence-Based Medicine|February 14, 2023
Rapid access to innovative medicinal products while ensuring relevant health technology assessment. Position of the French National Authority for HealthAntoine Vanier, Judith Fernandez, Sophie Kelley, et al.
BMC Nephrology|July 5, 2017
Worldwide view of nephropathic cystinosis: results from a survey from 30 countriesAurélia Bertholet-Thomas, Julien Berthiller, Velibor Tasic, et al.
Pageof 23